Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising early results for rare psoriasis drug

NCT ID NCT03619902

Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a drug called imsidolimab in 8 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition. The drug is an antibody that targets inflammation. Researchers measured how well it worked using skin scores and other health markers. The goal was to see if the drug could safely control symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Imsidolimab (a lab-made antibody that targets inflammation)
What this could lead to
If successful, this could point toward a new treatment option to control flare-ups in people with generalized pustular psoriasis.
What could go wrong
This is a very small early-phase trial with only 8 participants, so results may not apply to everyone. The drug may not work in larger studies or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

8 people

The number who actually took part.

Started

Jan 2019

Finished

Jan 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of active GPP * Japanese Dermatology Association (JDA) severity index total score of at least 6 and erythema with pustules accounting for at least 10% of body surface area or a moderate severity score on Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) * Must be candidates for systemic therapy or phototherapy Exclusion Criteria: * Erythrodermic, guttate psoriasis, drug induced GPP * Any other ongoing inflammatory disease that interfere with the Investigator's ability to evaluate the subject's response to therapy * History of recurrent or chronic infection * ongoing use of psoriasis prohibited medication Other protocol-defined inclusion/exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Generalized pustular psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized pustular psoriasis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Generalized pustular psoriasis

Contacts and locations

Locations

  • Site 100

    Ann Arbor, Michigan, 48109, United States

  • Site 101

    Indianapolis, Indiana, 46250, United States

  • Site 102

    Encino, California, 91436, United States

  • Site 104

    Miami, Florida, 33316, United States

  • Site 105

    Largo, Florida, 33771, United States

  • Site 201

    London, United Kingdom

  • Site 202

    Salford, United Kingdom

  • Site 203

    Newcastle upon Tyne, United Kingdom

  • Site 301

    Rzeszów, 35-055, Poland

  • Site 302

    Lodz, Poland

  • Site 303

    Lodz, 90-436, Poland

  • Site 304

    Olsztyn, 10-229, Poland

  • Site 501

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.